Long acting sustained-release formulation containing...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 9/16 (2006.01) A61K 31/381 (2006.01) A61K 47/30 (2006.01) A61P 25/16 (2006.01)

Patent

CA 2581143

Long acting sustained-release formulation for treating Parkinson's Disease, which comprises effective amount of the dopamine receptor agonist and the biodegradable pharmaceutical polymer excipient. The weight amount of the dopamine receptor agonist in the formulation is 5-50 %, and the weight amount of the pharmaceutical polymer excipient in that is 50-95 %.

La présente invention concerne une formulation à libération lente et prolongée pour le traitement de la maladie de Parkinson, qui comprend une quantité efficace de l~agoniste du récepteur de la dopamine et l~excipient polymère pharmaceutique biodégradable. La quantité en poids de l~agoniste du récepteur de la dopamine dans la formulation est de 5 à 50 % et la quantité en poids de l~excipient polymère pharmaceutique biodégradable dans la formulation est de 50 à 95 %.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Long acting sustained-release formulation containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Long acting sustained-release formulation containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long acting sustained-release formulation containing... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1741298

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.